Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
Autor: | Sara Ghorashian, Elad Jacoby, Barbara De Moerloose, Susana Rives, Denise Bonney, Geoff Shenton, Peter Bader, Nicole Bodmer, Agueda Molinos Quintana, Blanca Herrero, Mattia Algeri, Franco Locatelli, Kim Vettenranta, Berta Gonzalez, Andishe Attarbaschi, Stephen Harris, Jean Pierre Bourquin, André Baruchel |
---|---|
Přispěvatelé: | University of Zurich, Baruchel, André, University of Helsinki, Clinicum, Children's Hospital, Lastentautien yksikkö, HUS Children and Adolescents |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
CELL THERAPY
Receptors Chimeric Antigen Blinatumomab 3122 Cancers 2720 Hematology Receptors Antigen T-Cell Biology and Life Sciences Infant 610 Medicine & health Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA 10036 Medical Clinic Child Preschool Medicine and Health Sciences Humans Adults Retrospective Studies |
Zdroj: | LANCET HAEMATOLOGY |
ISSN: | 2352-3026 |
Popis: | [Background]: Children aged younger than 3 years were excluded from the ELIANA phase 2 trial of tisagenlecleucel in children with acute lymphoblastic leukaemia. The feasibility, safety, and activity of tisagenlecleucel have not been defined in this group, the majority of whom have high-risk (KMT2A-rearranged) infant acute lymphoblastic leukaemia and historically poor outcomes despite intensification of chemotherapy, and for whom novel therapies are urgently needed. We aimed to provide real-world outcome analysis of the feasibility, activity, and safety of tisagenlecleucel in younger children and infants with acute lymphoblastic leukaemia. [Methods]. We did an international, multicentre, retrospective cohort study at 15 hospitals across ten countries in Europe. Eligible patients were children aged younger than 3 years at screening between Sept 1, 2018, and Sept 1, 2021, who were screened for tisagenlecleucel therapy for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia according to licensed indications. Patients received a single intravenous infusion of tisagenlecleucel. We tracked chimeric antigen receptor T-cell therapy outcomes using a standardised data reporting form. Overall survival, event-free survival, stringent event-free survival, B-cell aplasia, and toxicity were assessed in all patients who received a tisagenlecleucel infusion. [Findings]: 38 eligible patients were screened, of whom 35 (92%) received a tisagenlecleucel infusion. 29 (76%) of 38 patients had KMT2A-rearranged acute lymphoblastic leukaemia, and 25 (66%) had relapsed after previous allogeneic haematopoietic stem-cell transplantation (HSCT). Patients had previously received a median of 2 lines (IQR 2–3) of (non-HSCT) therapy. Seven (18%) of 38 patients had received inotuzumab and 14 (37%) had received blinatumomab. After a median of 14 months (IQR 9–21) of follow-up, overall survival at 12 months after tisagenlecleucel infusion was 84% (64–93; five patients had died), event-free survival was 69% (47–83; nine events), and stringent event-free survival was 41% (23–58; 18 events). The probability of ongoing B-cell aplasia was 70% (95% CI 46–84; seven events) at 12 months. Adverse events included cytokine release syndrome, which occurred at any grade in 21 (60%) of 35 patients and at grade 3 or worse in five (14%), and neurotoxicity at any grade in nine (26%), none of which were severe. Measurable residual disease-negative complete response with or without haematological recovery occurred in 24 (86%) of 28 patients who had measurable disease. [Interpretation]: These data suggest that tisagenlecleucel has antitumour activity and has an acceptable safety profile for young children and infants with B-cell precursor acute lymphoblastic leukaemia. |
Databáze: | OpenAIRE |
Externí odkaz: |